Advertisement #1
Home Tags CD19

Tag: CD19

Cancer Immunotherapy. Shown here is a pseudo-colored scanning electron micrograph of an oral squamous cancer cell (white) being attacked by two cytotoxic T cells (red), part of a natural immune response. Nanomedicine researchers are creating personalized cancer vaccines by loading neoantigens identified from the patient's tumor into nanoparticles. When presented with immune stimulants, this activates the patient's own immune system, leading to expansion of tumor-specific cytotoxic T cells.

Carl H. June, MD, FAACR, Receives 2023 AACR Award for Lifetime...

Editorial Team -

ALL Patients With Certain Gene Regulation Patterns May Be Less Likely...

Editorial Team -

Orthogonal IL-2 Ligand Drives Deeper and More Durable Response of CD-19...

Peter Hofland -
Attendees and Speakers during Friday Scientific Workshop on Tumor Immune Interactions in Lymphoid Malignancies at the American Society of Hematology 60th Annual Meeting at the Orange County Convention Center on, Friday December 6, 2019. Photo courtesy © 2019 ASH/Matt Herp 2019

ASH 2020: Reaching a Broader Patient Population with Cellular Therapies for...

Peter Hofland -
T-cells attacking a cancer cell.

CAR T-cell Therapies for the Treatment of Patients with Acute Lymphoblastic...

Editorial Team -

U.S. FDA Accepts Priority Review for Lisocabtagene Maraleucel R/R Large...

Editorial Team -
Cg render of t-cells

Phase I ZUMA-3 Results for KTE-X19 in ALL Show High Rates...

Peter Hofland -

First CAR T-Cell Immunotherapy Trial for Children and Young Adults With...

Peter Hofland -

LATEST NEWS

Advertisment #12
© 2001 - 2023 Sunvalley Communication, LLC. All Rights Reserved.

X